Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy + Cetuximab in Esophageal Adenocarcinoma
NCT00551759Phase 2Terminated
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2008
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Eastern Cooperative Oncology Group. Started Oct 2008; status: terminated.
02
Drugs
KL-140
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00551759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551759.